105 related articles for article (PubMed ID: 32915111)
1. Eltrombopag, oral immunosuppressant and androgen combination therapy in twelve patients with refractory severe aplastic anemia.
Gao Q; Zhang L; Zhao X; Zhu Y; Peng G; Li Y; Li Y; Li J; Song L; Ye L; Fan H; Zhou K; Yang W; Yang Y; Jing L; Zhang F
Hematology; 2020 Dec; 25(1):341-347. PubMed ID: 32915111
[No Abstract] [Full Text] [Related]
2. Eltrombopag for the treatment of aplastic anemia: current perspectives.
Lum SH; Grainger JD
Drug Des Devel Ther; 2016; 10():2833-2843. PubMed ID: 27695288
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of avatrombopag in combination with immunosuppressive therapy in treatment-naïve and relapsed/refractory severe aplastic anaemia: protocol for the DIAAMOND-Ava-FIRST and DIAAMOND-Ava-NEXT Bayesian Optimal Phase II trials.
McQuilten Z; Heritier S; Fox L; Fox V; Young L; Blombery P; Cunningham I; Curnow J; Higgins A; Hiwase DK; Filshie R; Firkin F; Lacaze P; Mason K; Mills AK; Pepperell D; Patil S; Stevenson W; Szer J; Waters N; Wilson K; Ting S; Wood E
BMJ Open; 2024 Jan; 14(1):e076246. PubMed ID: 38238183
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of immunosuppressive therapy combined with eltrombopag for severe aplastic anemia: a systematic review and meta-analysis.
Zhang Y; Li J; Li X; Geng Q; Xie Y; Zhang G; Wei M; Ma Y
Syst Rev; 2024 Apr; 13(1):101. PubMed ID: 38576005
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of eltrombopag in Chinese patients with refractory or relapsed severe aplastic anemia.
Chang H; He G; Fu R; Li F; Han B; Li T; Liu L; Mittal H; Jin H; Zhang F
Sci Rep; 2023 Nov; 13(1):18955. PubMed ID: 37919313
[TBL] [Abstract][Full Text] [Related]
6. Eltrombopag-cyclosporin A in treating severe aplastic anaemia.
Sathiamoorthy KS; Manikandan S
Lancet Haematol; 2024 Jun; 11(6):e397. PubMed ID: 38796186
[No Abstract] [Full Text] [Related]
7. Real-world outcomes with immunosuppressive therapy for aplastic anemia in patients treated at the University of Michigan.
Foucar CE; Foley DH; Aldous J; Burke PW; Pettit KR; Benitez LL; Perissinotti AJ; Marini BL; Boonstra P; Bixby DL
Eur J Haematol; 2024 Mar; 112(3):424-432. PubMed ID: 37929654
[TBL] [Abstract][Full Text] [Related]
8. Plain language summary of RACE study results: addition of eltrombopag to standard treatment of severe aplastic anemia.
de Latour RP; Kulasekararaj A; Iacobelli S; Griffin M; Halkes CJ; Dufour C; Risitano AM
Immunotherapy; 2024 Feb; 16(3):135-142. PubMed ID: 38088156
[TBL] [Abstract][Full Text] [Related]
9. Consideration of ATG-free therapy with eltrombopag and cyclosporine for severe aplastic anaemia.
Groarke EM
Lancet Haematol; 2024 Mar; 11(3):e173-e174. PubMed ID: 38335977
[No Abstract] [Full Text] [Related]
10. Eltrombopag-cyclosporin A in treating severe aplastic anaemia - Authors' reply.
Scheinberg P
Lancet Haematol; 2024 Jun; 11(6):e398. PubMed ID: 38796188
[No Abstract] [Full Text] [Related]
11. Activity and safety of eltrombopag in combination with cyclosporin A as first‑line treatment of adults with severe aplastic anaemia (SOAR): a phase 2, single-arm study.
Scheinberg P; Finelli C; Montaňo-Figueroa EH; Vallejo C; Norasetthada L; Calado RT; Turgut M; Peffault de Latour R; Kriemler-Krahn U; Haenig J; Clark J; Jang J
Lancet Haematol; 2024 Mar; 11(3):e206-e215. PubMed ID: 38335978
[TBL] [Abstract][Full Text] [Related]
12. Eltrombopag combined with immunosuppressive therapy for pediatric severe aplastic anemia.
Yang B; Fu L; Li H; Chen H; Zhang R; Yao J; Zhang L; Wu R; Ma J
Pediatr Res; 2024 May; ():. PubMed ID: 38822136
[TBL] [Abstract][Full Text] [Related]
13. Deciphering treatment patterns in non-severe/moderate aplastic anemia: an international observational study.
Fattizzo B; Gurnari C; Cassanello G; Bortolotti M; Awada H; Giammarco S; Consonni D; Sica S; Gandhi S; Trikha R; Large J; Salter S; Maciejewski JP; Barcellini W; Kulasekararaj AG
Leukemia; 2023 Dec; 37(12):2479-2485. PubMed ID: 37794100
[TBL] [Abstract][Full Text] [Related]
14. The long-term outcomes and safety of severe aplastic anemia treated with porcine antilymphocyte globulin plus cyclosporine, with or without thrombopoietin receptor agonists: a double-center retrospective study.
Xu S; Xiao Y; Liang X; Lu Y; Deng M
Expert Rev Hematol; 2024; 17(4-5):181-188. PubMed ID: 38687471
[TBL] [Abstract][Full Text] [Related]
15. Multicenter evaluation of the addition of eltrombopag to immunosuppressive therapy for adults with severe aplastic anemia.
Shinn LT; Benitez LL; Perissinotti AJ; Reid JH; Buhlinger KM; van Deventer H; Barth D; Wagner CB; Zacholski K; Desai R; Soule A; Stump SE; Weis TM; Bixby D; Burke P; Pettit K; Marini BL
Int J Hematol; 2023 Dec; 118(6):682-689. PubMed ID: 37882977
[TBL] [Abstract][Full Text] [Related]
16. Budget Impact Of Eltrombopag As First-Line Treatment For Severe Aplastic Anemia In The United States.
Tremblay G; Said Q; Roy AN; Cai B; Ashton Garib S; Hearnden J; Forsythe A
Clinicoecon Outcomes Res; 2019; 11():673-681. PubMed ID: 31814747
[TBL] [Abstract][Full Text] [Related]
17. [Reassessing the six months prognosis of patients with severe or very severe aplastic anemia without hematological responses at three months after immunosuppressive therapy].
Hu XR; Zhao X; Zhang L; Jing LP; Yang WR; Li Y; Ye L; Zhou K; Li JP; Peng GX; Fan HH; Li Y; Yang Y; Xiong YZ; Zhang FK
Zhonghua Xue Ye Xue Za Zhi; 2022 May; 43(5):393-399. PubMed ID: 35680597
[No Abstract] [Full Text] [Related]
18. Cyclosporine monotherapy for severe aplastic anemia: a developing country experience.
Al-Ghazaly J; Al-Dubai W; Al-Jahafi AK; Abdullah M; Al-Hashdi A
Ann Saudi Med; 2005; 25(5):375-9. PubMed ID: 16270758
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of eltrombopag in patients with aplastic anemia: a systematic review and meta-analysis of randomized controlled trials.
Guo H; Liu C; Kang L; Liu C; Liu Y
Hematology; 2024 Dec; 29(1):2335419. PubMed ID: 38553907
[TBL] [Abstract][Full Text] [Related]
20. Partial SAA patients benefit from delayed response of IST.
Wang T; Wang C; Liu C; Shao Z; Fu R
Front Immunol; 2023; 14():1067977. PubMed ID: 36845107
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
